Ivermectin is an effective drug for the treatment of human onchocerciasis, a disease caused by the parasitic filarial nematode Onchocerca volvulus. When humans are treated, the microfilariae normally found in the skin are rapidly and very nearly completely eliminated. Nonetheless, after a delay, microfilariae gradually reappear in the skin. This study is concerned with the causes of this delay. Hypotheses are tested by comparing the results of model calculations with skin microfilaria counts collected from 114 patients during a trial of five annual treatments in the focus area of Asubende, Ghana. The results obtained strongly suggest that annual treatment with ivermectin causes an irreversible decline in microfilariae production of~30%/treatment. This result has important implications for public health strategies designed to eliminate onchocerciasis as a significant health hazard.The registration ofthe anthelminthic drug ivermectin (Mectizan; Merck, Rahway, NJ) in 1987 was a landmark in the control of human onchocerciasis or river blindness, a parasitic disease caused by the filarial nematode Onchocerca volvulus. Oral administration in a standard dose of 150-200 j.Lg/kg of body weight is followed by rapid elimination of microfilariae (Mf) from the skin and gradual reduction of ocular Mf levels [1]. Side effects are generally mild. This makes ivermectin a better therapeutic option than diethylcarbamazine, which is often accompanied by severe Mazotti reactions and ocular damage. Ivermectin also produces a longer suppression ofMfrepopulation of the skin [2,3]. To explain this difference, which was obvious in all studies done so far, the effects of ivermectin on adult parasites were studied.Adult female parasites in treated persons show an interruption of the normal embryogenesis, but after a single treatment, this appears to be reversible for most of the worms [4,5]. Excess worm mortality was not observed after a single treatment [1, 2, 6], although significant numbers of dead and mori-